Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS

NCT02576301 is registered in ClinicalTrials.gov with Mateon Therapeutics as lead sponsor.

NCT NCT02576301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02576301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS
Lead sponsor
Mateon Therapeutics
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2015
Completion date
October 31, 2020
Enrollment
105 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, myelodysplastic syndromes